Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Q&A: Final Questions on Glioblastoma and Neuroimaging

June 13th 2024

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.

Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment

June 13th 2024

Medical experts engage in a discussion on the PET RANO 1.0 Response Criteria, which provides guidelines for evaluating treatment response in patients with brain tumors, taking into account both measurable PET-positive disease and non-PET-positive disease, as assessed through initial baseline imaging and subsequent follow-up scans.

Dr Ahluwalia on the Incidence of Brain Metastases in RCC

June 10th 2024

Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.

Polling Question: Utility of Amino Acid PET

June 6th 2024

Nathalie Albert, MD, explains that amino acid PET scans can be valuable tools in monitoring disease progression and assessing a patient's response to treatment, while also exploring the optimal timing for utilizing these scans in the overall management of brain tumors.

Advanced Modalities of Neuroimaging in the Management of Glioblastoma

June 6th 2024

Nathalie Albert, MD, delves into advanced MRI techniques such as perfusion imaging, functional MRI, MR spectroscopy, and DEMARCATE, while also exploring the role of PET imaging, particularly those utilizing glucose and amino acid tracers in neuroimaging.

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

June 3rd 2024

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

AGuIX Receives FDA Fast Track Designation in Glioblastoma

May 30th 2024

AGuIX has been granted FDA fast track designation in malignant gliomas and glioblastoma.

Conventional Neuroimaging: CT scans & MRI Scans in Glioblastoma

May 30th 2024

Experts engage in a comprehensive discussion on conventional imaging techniques, evaluating the strengths and limitations of CT and MRI scans, particularly in delineating tumor borders and distinguishing between tumors and the surrounding central nervous system tissue.

Leveraging Neuroimaging Modalities and Guidelines in Glioblastoma

May 30th 2024

Medical experts discuss the use of various neuroimaging techniques, such as MRIs, CT scans, and PET scans, emphasizing that due to limitations of MRI it is frequently combined with other modalities to obtain more comprehensive information.

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

May 28th 2024

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

Broadening Differentials in Brain-Metastatic Prostate Cancer Expand Diagnostic Horizons

May 28th 2024

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

Exploring Vaccine Approaches for Immunoprevention in Low-Grade Glioma

May 22nd 2024

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

April 25th 2024

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

April 23rd 2024

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

FDA Grants Accelerated Approval to Tovorafenib for Pediatric Relapsed/Refractory BRAF+ Low-Grade Glioma

April 23rd 2024

The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes

April 17th 2024

The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.

FDA Grants Fast Track Designation to TLX101-CDx for Imaging Progressive/Recurrent Glioma

April 16th 2024

The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.